Merck: JPMorgan Chase Co’s Largest Q3 Healthcare Stock Position

Wall St. Watchdog reveals information regarding JPMorgan Chase Co’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 363 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $16.734 billion.

  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, JPMorgan Chase Co reported holding 52,519,744 shares with a market value of $1,853,421,814. This comprised 0.87% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 59,766,649 shares with a market value of $1,954,369,468. This comprised 1.12% of the total portfolio. The net change in shares for this position over the two quarters is 7,246,905. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, JPMorgan Chase Co reported holding 85,167,280 shares with a market value of $1,754,446,000. This comprised 0.83% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 92,455,490 shares with a market value of $1,634,613,091. This comprised 0.94% of the total portfolio. The net change in shares for this position over the two quarters is 7,288,210. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, JPMorgan Chase Co reported holding 23,306,521 shares with a market value of $1,550,349,699. This comprised 0.73% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 24,046,061 shares with a market value of $1,531,493,592. This comprised 0.88% of the total portfolio. The net change in shares for this position over the two quarters is 739,540. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, JPMorgan Chase Co reported holding 25,821,447 shares with a market value of $1,358,724,514. This comprised 0.64% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 20,260,418 shares with a market value of $1,036,117,764. This comprised 0.6% of the total portfolio. The net change in shares for this position over the two quarters is -5,561,029. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Biogen Idec Inc. (NASDAQ:BIIB): On 06/30/2011, JPMorgan Chase Co reported holding 10,047,010 shares with a market value of $1,074,226,291. This comprised 0.51% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 10,196,893 shares with a market value of $949,840,599. This comprised 0.55% of the total portfolio. The net change in shares for this position over the two quarters is 149,883. About Company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, JPMorgan Chase Co reported holding 17,208,367 shares with a market value of $887,607,601. This comprised 0.42% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 18,743,212 shares with a market value of $864,436,917. This comprised 0.5% of the total portfolio. The net change in shares for this position over the two quarters is 1,534,845. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Covidien Plc (NYSE:COV): On 06/30/2011, JPMorgan Chase Co reported holding 17,013,345 shares with a market value of $905,620,347. This comprised 0.43% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 18,689,812 shares with a market value of $824,220,681. This comprised 0.47% of the total portfolio. The net change in shares for this position over the two quarters is 1,676,467. About Company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, JPMorgan Chase Co reported holding 12,666,594 shares with a market value of $764,048,946. This comprised 0.36% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 10,888,069 shares with a market value of $674,080,350. This comprised 0.39% of the total portfolio. The net change in shares for this position over the two quarters is -1,778,525. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Humana Inc. (NYSE:HUM): On 06/30/2011, JPMorgan Chase Co reported holding 7,604,797 shares with a market value of $612,490,357. This comprised 0.29% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 9,261,365 shares with a market value of $673,579,108. This comprised 0.39% of the total portfolio. The net change in shares for this position over the two quarters is 1,656,568. About Company: Humana Inc. is a managed health care company with medical members located in the United States and Puerto Rico. The Company offers coordinated health care through health maintenance organizations, preferred provider organizations, point-of-service plans, and administrative services products. Humana offers its products to employer groups, government-sponsored plans, and individuals.
  • Becton Dickinson And Company (NYSE:BDX): On 06/30/2011, JPMorgan Chase Co reported holding 6,949,065 shares with a market value of $598,800,918. This comprised 0.28% of the total portfolio. On 09/30/2011, JPMorgan Chase Co reported holding 5,452,815 shares with a market value of $399,800,394. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is -1,496,250. About Company: Becton, Dickinson and Company manufactures and sells a variety of medical supplies and devices and diagnostic systems. The Company’s products are used by health care professionals, medical research institutions, and the general public. Becton’s products are marketed worldwide.

(Note: Data regarding JPMorgan Chase Co’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>